After-Hours Stock Movers 03/17: (UPST) (WSM) (FIVE) Higher; (TBIO) (CFRX) (SLDB) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Solid Biosciences (SLDB) Prices 21.74M Share Common Offering at $5.75/Sh
March 19, 2021 6:02 AM EDTSolid Biosciences Inc., (NASDAQ: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it has priced an underwritten public offering of 21,739,131 shares of its common stock at a public offering price of $5.75 per share, for total gross proceeds of $125.0 million, before... More
Upstart (UPST) Explodes 40% on Earnings Beat and Strong Guidance, Triggering Upgrade to 'Outperform'
March 18, 2021 8:00 AM EDTUpstart (NASDAQ: UPST) stock exploded over 40% in pre-open trading Thursday after the company reported strong results in its first financial results as a public company.
The digital lending AI company reported a net income of $1.03 million for the fourth quarter. On an adjusted basis, UPST said it earned $0.07 per share to top the market expectations of $0.02 per share.
Revenue came in at $86.7 million, again higher than $73.5 million expected from the Street, and representing a y-o-y increase of 39%. Last year, the company made a profit of $0.10 per share.
Were... More
ContraFect (CFRX) Prices 10M Share Common Offering at $5/Sh
March 18, 2021 6:03 AM EDTContraFect Corporation (NASDAQ: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $5.00 per share. ContraFect has also granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its common... More
